Aterian (ATER) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
15 May, 2026Executive summary
Special Meeting will seek approval for the sale of substantially all assets to Trademark Global for $18 million, subject to adjustments, and related strategic transactions, including a significant investment by David E. Lazar through preferred stock issuance for $7 million gross proceeds.
The Board unanimously recommends voting in favor of all proposals, citing persistent macroeconomic headwinds, liquidity challenges, and the need for strategic realignment.
The Asset Sale and Investment Transaction are designed to return value to shareholders, pay down liabilities, and reposition the company for future growth in new sectors.
Net proceeds available for distribution to shareholders are estimated between $10.6 million and $14.2 million, or $0.85 to $1.14 per share.
Voting matters and shareholder proposals
Eight proposals will be voted on: Asset Sale, Director Elections, Change of Control, Related Party Issuance, Issuance of Common Stock, Reverse Stock Split, Authorized Stock Increase, and Adjournment.
Proposals 3, 4, and 5 (Change of Control, Related Party, Issuance) are interdependent and must all be approved to take effect.
The Board recommends voting FOR all proposals.
Board of directors and corporate governance
Board currently consists of five members, with a classified structure (three classes).
Two new nominees, Avraham Ben-Tzi and David Natan, are proposed for election; if elected, several current directors will step down.
David E. Lazar, incoming CEO and Chair, has the right to nominate additional directors post-closing.
Board committees include Audit and Compensation, both comprised of independent directors.
Latest events from Aterian
- Major asset sale and recapitalization planned amid steep losses and going concern risks.ATER
Q1 202615 May 2026 - Asset sale and strategic investment will transfer control to David Lazar, pending shareholder approval.ATER
Proxy filing29 Apr 2026 - Revenue dropped 30% and net loss widened as tariffs and weak demand pressured results.ATER
Q4 202523 Mar 2026 - Q2 guidance raised and new leadership named; profitability targeted for H2 2024.ATER
Investor Update3 Feb 2026 - Net loss narrowed and adjusted EBITDA turned positive, but going concern risks persist.ATER
Q2 20242 Feb 2026 - Turnaround delivers EBITDA profitability; focus shifts to omnichannel and organic growth.ATER
17th Annual LD Micro Main Event Conference17 Jan 2026 - Gross margin rose to 60.3% as net loss narrowed and adjusted EBITDA turned positive.ATER
Q3 202415 Jan 2026 - Margins improved, losses narrowed in 2024; 2025 targets growth and break-even EBITDA.ATER
Q4 202426 Dec 2025 - Annual meeting to elect a director and ratify a new auditor, with strong governance practices.ATER
Proxy Filing1 Dec 2025